Disability and quality-of-life are not influenced by the prevalence of autoantibodies in early rheumatoid arthritis patients--results of the Brasília Cohort

Rev Bras Reumatol. 2012 Dec;52(6):824-9.
[Article in English, Portuguese]

Abstract

Introduction: Although many studies have suggested that the presence of autoantibodies, such as rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) in rheumatoid arthritis (RA) are predictors of joint damage, the association with disability and quality of life questionnaires are not known.

Objectives: To evaluate the correlation between the Health Assessment Questionnaire (HAQ) and the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) scores with serological markers, such as RF, anti-CCP, and anti-citrullinated vimentin (anti-Sa).

Patients and methods: Sixty five patients with early RA (ERA) from the Brasília Cohort of ERA were evaluated. Serology tests (ELISA) for RF (IgM, IgG, and IgA), anti-CCP (CCP2, CCP3, and CCP3.1), and anti-Sa were performed, with the application of the HAQ and SF-36 questionnaires in the initial evaluation.

Results: The mean age was 45 years, with a female predominance (86%). At the initial evaluation, RF was positive in 32 individuals (49.23%), anti-CCP in 34 (52.3%), and anti-Sa in nine (13.8%). The initial HAQ score was 1.8. The SF-36 scores were as follow: role-emotional, 19.3; social functioning, 43.1; bodily pain, 25.43; general health, 57.6; mental health, 48.1; vitality, 49.5; role-physical, 4.6; and physical functioning, 24.7. The HAQ and SF-36 scores did not vary with autoantibody levels.

Conclusion: In many patients, ERA has a major impact on physical ability and health-related quality of life. Although RF and anti-CCP tests have been related with joint destruction and worse clinical prognosis, there is no correlation with the results of questionnaires of quality of life and disability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Arthritis, Rheumatoid / blood*
  • Arthritis, Rheumatoid / immunology*
  • Autoantibodies / blood*
  • Cohort Studies
  • Disability Evaluation*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Peptides, Cyclic / immunology
  • Quality of Life*
  • Rheumatoid Factor / immunology
  • Surveys and Questionnaires
  • Vimentin / immunology

Substances

  • Autoantibodies
  • Peptides, Cyclic
  • Vimentin
  • cyclic citrullinated peptide
  • Rheumatoid Factor